The company is expected to report Revenue/PAT CAGR of 11.1% and 11.3% 0ver FY21-FY24E backed by stable sales in the Duphaston brand, an increase in volume in the Thyronorm brand, and a pick-up in the IPM growth. Therefore, we recommend a BUY rating on the stock with a Target Price of Rs 20,000/share